Recently, our group revealed a regulatory mechanism for cellular ROS production and the progression of breast cancer in which HBXIP functions as a critical modulator of the classical Keap-Nrf2-antioxidant response element (ARE) pathway9. The gene discussed is LAMTOR5; the disease is breast cancer.